CHERYL A AYLESWORTH M.D. NPI 1386655603

NPI Details

Cheryl A Aylesworth, M.D. is a specialist in Wheaton, MD with 37 years of experience. The provider is an individual educated and trained in an applied knowledge discipline used in the performance of work at a level requiring knowledge and skills beyond or apart from that provided by a general education or liberal arts degree. Cheryl A Aylesworth, M.D. NPI is 1386655603. The provider is registered as an individual entity type.

The NPPES NPI record indicates the provider is a female.

Education
Medical School: TUFTS UNIVERSITY SCHOOL OF MEDICINE
Graduation Year:1989

The provider's business location address is:

2730 UNIVERSITY BLVD W
400
WHEATON, MD
ZIP 20902-905
Phone: (301) 942-9220
Fax: (301) 942-9223

The NPI 1386655603 is registered in the Medicare Provider, Enrollment, Chain and Ownership System (PECOS). The provider is legally eligible to order and refer Part B (Clinical Laboratory and Imaging), Durable Medical Equipment, Part A Home Health Agency (HHA), Power Mobility Devices.

The following top HCPCS codes were publicly reported for this provider under the Medicare program for the year 2016. The reported codes are based on the top codes for each available Medicare specialty, excluding evaluation and management codes.

• Injection, ferric carboxymaltose, 1 mg (HCPCS:J1439)
• Injection, darbepoetin alfa, 1 microgram (non-esrd use) (HCPCS:J0881)
• Injection, pembrolizumab, 1 mg (HCPCS:J9271)
• Injection, paclitaxel, 1 mg (HCPCS:J9267)
• Injection, denosumab, 1 mg (HCPCS:J0897)
• Injection, aprepitant, 1 mg (HCPCS:J0185)
• Injection, daratumumab, 10 mg and hyaluronidase-fihj (HCPCS:J9144)
• Injection, iron sucrose, 1 mg (HCPCS:J1756)
• Injection, bortezomib (velcade), 0.1 mg (HCPCS:J9041)
• Injection, immune globulin, (octagam), intravenous, non-lyophilized (e.g., liquid), 500 mg (HCPCS:J1568)
• Injection, rituximab-pvvr, biosimilar, (ruxience), 10 mg (HCPCS:Q5119)
• Injection, dexamethasone sodium phosphate, 1 mg (HCPCS:J1100)
• Complete blood cell count (red cells, white blood cell, platelets), automated test and automated differential white blood cell count (HCPCS:85025)
• Blood test, comprehensive group of blood chemicals (HCPCS:80053)
• Injection, fulvestrant, 25 mg (HCPCS:J9395)
• Injection, granisetron hydrochloride, 100 mcg (HCPCS:J1626)
• Established patient office or other outpatient visit, 20-29 minutes (HCPCS:99213)
• Injection, palonosetron hcl, 25 mcg (HCPCS:J2469)
• Gammaglobulin (immune system protein) measurement (HCPCS:82784)
• Established patient office or other outpatient visit, 30-39 minutes (HCPCS:99214)
• Administration of chemotherapy into vein, 1 hour or less (HCPCS:96413)
• Injection of additional new drug or substance into vein (HCPCS:96375)
• Injection, gemcitabine hydrochloride, not otherwise specified, 200 mg (HCPCS:J9201)
• Injection of drug or substance under skin or into muscle (HCPCS:96372)
• Infusion into a vein for therapy, prevention, or diagnosis, additional sequential infusion, 1 hour or less (HCPCS:96367)
• Injection, pegfilgrastim, excludes biosimilar, 0.5 mg (HCPCS:J2506)
• Lactate dehydrogenase (enzyme) level (HCPCS:83615)
• Injection, leucovorin calcium, per 50 mg (HCPCS:J0640)
• Injection, carboplatin, 50 mg (HCPCS:J9045)
• Iron level (HCPCS:83540)
• Iron binding capacity (HCPCS:83550)
• Injection, diphenhydramine hcl, up to 50 mg (HCPCS:J1200)
• Ferritin (blood protein) level (HCPCS:82728)
• Infusion into a vein for therapy, prevention, or diagnosis, 1 hour or less (HCPCS:96365)
• Administration of non-hormonal anti-neoplastic chemotherapy under skin or into muscle (HCPCS:96401)
• Injection, zoledronic acid, 1 mg (HCPCS:J3489)
• Injection, fluorouracil, 500 mg (HCPCS:J9190)
• Administration of hormonal anti-neoplastic chemotherapy under skin or into muscle (HCPCS:96402)
• Measurement of substance using immunoassay technique (HCPCS:83520)
• Carcinoembryonic antigen (cea) protein level (HCPCS:82378)
• Immunologic analysis for detection of tumor antigen, quantitative; ca 15-3 (HCPCS:86300)
• Unclassified drugs (HCPCS:J3490)
• Administration of additional new drug or substance into vein, 1 hour or less (HCPCS:96417)
• Administration of chemotherapy into vein, each additional hour (HCPCS:96415)
• Immunologic analysis for detection of tumor antigen, quantitative; ca 125 (HCPCS:86304)
• Insertion of needle into vein for collection of blood sample (HCPCS:36415)
• Infusion into a vein for therapy, prevention, or diagnosis, each additional hour (HCPCS:96366)
• Leuprolide acetate (for depot suspension), 7.5 mg (HCPCS:J9217)
• Uric acid level, blood (HCPCS:84550)
• Blood test, thyroid stimulating hormone (tsh) (HCPCS:84443)
• New patient office or other outpatient visit, 60-74 minutes (HCPCS:99205)
• Follow-up hospital inpatient care per day, typically 15 minutes (HCPCS:99231)
• Injection, vitamin b-12 cyanocobalamin, up to 1000 mcg (HCPCS:J3420)
• Established patient office or other outpatient visit, 10-19 minutes (HCPCS:99212)
• New patient office or other outpatient visit, 45-59 minutes (HCPCS:99204)
• Administration of additional new drug or substance into vein using push technique (HCPCS:96411)
• Irrigation of implanted venous access drug delivery device (HCPCS:96523)
• Follow-up hospital inpatient care per day, typically 25 minutes (HCPCS:99232)
• Infusion into a vein for therapy, prevention, or diagnosis concurrent with another infusion (HCPCS:96368)
• Drawing of blood for a medical problem (HCPCS:99195)
• Measurement c-reactive protein for detection of infection or inflammation (HCPCS:86140)
• Manual urinalysis test with examination using microscope, non-automated (HCPCS:81000)
• Red blood cell sedimentation rate, to detect inflammation, non-automated (HCPCS:85651)
• Haptoglobin (serum protein) level (HCPCS:83010)
• Injection, tixagevimab and cilgavimab, for the pre-exposure prophylaxis only, for certain adults and pediatric individuals (12 years of age and older weighing at least 40kg) with no known sars-cov-2 exposure, who either have moderate to severely compromise (HCPCS:M0220)
• Telephone medical discussion with physician, 11-20 minutes (HCPCS:99442)
• Initial hospital inpatient care per day, typically 50 minutes (HCPCS:99222)
• Application of on-body injector for under skin injection (HCPCS:96377)
• Infusion, normal saline solution , 1000 cc (HCPCS:J7030)
• Infusion into a vein for hydration, 31-60 minutes (HCPCS:96360)
• Established patient office or other outpatient visit, 40-54 minutes (HCPCS:99215)
• Beta-2 microglobulin (protein) level (HCPCS:82232)
• Injection, methylprednisolone sodium succinate, up to 125 mg (HCPCS:J2930)

The enumeration date for this NPI number is 8/11/2006 and was last updated on 7/8/2007.

Taxonomy Codes

The NPI record includes the healthcare provider taxonomy classification, state license number and state of licensure. The following information regarding the scope of practice of this provider is available:

Other Identifiers

The following information regarding additional identifiers associated to this NPI record includes the other identifier number, identifier type, identifier state and issuer.